Skip to main content
      CAR-T Topic Panel: EULAR 2026
      PsA Topic Panel: EULAR 2026
      Dr. Sun et al. from Duke University presented abstract POS0692 during one of the poster sessions entitled, “Lupus patients with concurrent inflammatory activity and symptom burdens have the lowest medication adherence and experience distinct adherence barriers.” They evaluated differences in self-reported medication adherence and reasons for nonadherence across Type 1 & 2 SLE classification groups, with a prespecified focus on comparing
      A bridge to uncertainty?
      large #RCT of #baricitinib V #TNFi
      In
      Active #RA w #DVT/#VTE risk factor(s)

      Sl more VTE, #inf

      Janet Pope Janetbirdope

      4 days 14 hours ago
      A bridge to uncertainty? large #RCT of #baricitinib V #TNFi In Active #RA w #DVT/#VTE risk factor(s) Sl more VTE, #infection #SIE on #Bar NO increase #MACE Sl ⬆️#malignancy #VTE rate exceeded upper limit of a priori #CI So is this good news or not? #LB0009 @RheumNow #EULAR2026 https://t.co/CIfU7TL2TE
      The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented. Guidelines presented addressed several significant unmet need areas including PMR, GCA, Takayasu’s arteritis, Vaccinations in Rheumatic patients, Imaging in spondyloarthritis and classification criteria for the Anti-Synthetase Syndrome. Here are but a few of my favorites from a list of many quality sessions.
      Steroid use remain common in rheumatology, despite risks even low-dose, especially for older adults.
      "Steroids and Me"

      Jiha Lee JihaRheum

      5 days 8 hours ago
      Steroid use remain common in rheumatology, despite risks even low-dose, especially for older adults. "Steroids and Me" (Sam) provides online patient education ~5 minutes. @RheumNow #EULAR2026 POS1388
      TMP-SMX prophylaxis cuts PJP risk by 69% (RR 0.31) & mortality by 59% (RR 0.41) in immunosuppressed rheum dz pts —

      Dr. John Cush RheumNow

      5 days 9 hours ago
      TMP-SMX prophylaxis cuts PJP risk by 69% (RR 0.31) & mortality by 59% (RR 0.41) in immunosuppressed rheum dz pts —but ADRs are 26x more common. NNT=323, NNH=5. Risk-adapted approach recommended. #EULAR2026 POS1190 https://t.co/4yjD9CmySM
      Extended-release febuxostat (HR091506) vs standard febuxostat in gout. 442 patients, 36 weeks.

      SUA <300 μmol/L at W

      Antoni Chan MD (Prof) synovialjoints

      5 days 10 hours ago
      Extended-release febuxostat (HR091506) vs standard febuxostat in gout. 442 patients, 36 weeks. SUA <300 μmol/L at Week 36: 63.8% vs 40.7% (p<0.0001) A 23% difference on the most stringent urate target. Well tolerated and acceptable safety profile Abstr LB0008 @RheumNow https://t.co/PSrn7K5BVS
      #EULAR2026 LB0009 It’s like opening Pandora’s box! 2 Open Label RCTs Baricitinib vs TNF-i in RA & =>1 VTE ris

      Md Yuzaiful Md Yusof Yuz6Yusof

      5 days 10 hours ago
      #EULAR2026 LB0009 It’s like opening Pandora’s box! 2 Open Label RCTs Baricitinib vs TNF-i in RA & =>1 VTE risk: -VTE:Non-inferiority of BARI wasn’t met (in line with JAK profile) -No increase in MACE/Cancer (opposed to Oral-Surveillance: TOFA & =>1 MACE risk) @RheumNow #EULARBest https://t.co/nNwtJ3LbkD
      Baricitinib did not demonstrate non-inferiority w/ TNFi for first VTE in the RA-BRIDGE and RA-BRANCH trials.

      Identifyi

      sheila RHEUMarampa

      5 days 11 hours ago
      Baricitinib did not demonstrate non-inferiority w/ TNFi for first VTE in the RA-BRIDGE and RA-BRANCH trials. Identifying high-risk pts and individualizing tx is paramount. LB0009 @RheumNow #EULAR2026 https://t.co/MSiBq0FnEq
      Abstr LB0009

      Baricitinib vs TNFi in RA patients enriched for VTE risk. 3,640 patients. 3.7 years median follow-up.

      VTE

      Antoni Chan MD (Prof) synovialjoints

      5 days 11 hours ago
      Abstr LB0009 Baricitinib vs TNFi in RA patients enriched for VTE risk. 3,640 patients. 3.7 years median follow-up. VTE: HR 1.61 (95% CI 0.97–2.66) non-inferiority not demonstrated MACE: HR 1.06 no cardiovascular excess Serious infections: HR 1.32 (p<0.05) @RheumNow https://t.co/NSNRJi9B4r
      ×